Nuvectis Pharma Inc. reported its financial results for the full year ended December 31, 2025. Research and development expenses for the period totaled USD 18.15 million, while general and administrative expenses amounted to USD 9.42 million. The company recorded a finance income of USD 1.13 million. Operating loss for the year was USD 27.57 million, and net loss stood at USD 26.44 million. The total net loss attributable to common shareholders was USD 28.87 million, with basic and diluted net loss per common share at USD 1.32. Shareholders' equity as of December 31, 2025, was USD 18.41 million, and total liabilities and shareholders' equity reached USD 31.71 million. During the year, Nuvectis Pharma Inc. made significant progress in its NXP900 development program. The company highlighted advancements in the Phase 1b monotherapy study of NXP900, an oral small molecule inhibitor targeting the SRC Family of Kinases, including SRC and YES1. Management noted that these developments lay the groundwork for multiple potential data readouts in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.